Pimavanserin

Phase 3

ACADIA Pharmaceuticals Inc. (ACAD)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Jan '27

ACADPhase 2$4.4B

Pimavanserin Phase 2 Est. Readout

Pimavanserin• Agitation and Aggression in Alzheimer's Disease35

Jan 2027~Estimated

CT.gov

00%

Competitive Landscape

1 competitor in Agitation and Aggression in Alzheimer's Disease

View Full Landscape

Drug Information

Target Indication

Agitation and Aggression in Alzheimer's Disease

Clinical Trial

NCT03118947

Last updated: 12/29/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

ACAD

ACADIA Pharmaceuticals Inc.

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

CarbetocinPhase 3

Hyperphagia in Prader-Willi Syndrome

pimavanserin tartratePhase 3

Parkinson's Disease Psychosis

TrofinetidePhase 3

Rett Syndrome

Pimavanserin tartrate (ACP-103)Phase 3

Parkinson's Disease Psychosis

ACP-204Phase 3

Lewy Body Dementia Psychosis

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts